ArticleProceedings of the National Academy of Sciences of the United States of America2025
Digital SERS bioanalysis of single-enzyme biomarkers.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- AI/ML-Assisted SERS Biosensing for Biomolecular Detection: From Direct Spectral Response to Integrated Diagnostic Systems.Biosensors · 2026Review
- The Next Frontier in Vibrational Imaging: Chemically Designed Raman Probes Pass the Spectral Barrier.JACS Au · 2026Review
- Quantitative Surface-Enhanced Raman Spectroscopy: Challenges, Strategies, and Prospects.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Digital bioanalysis enables highly sensitive detection of biomolecules at the single-molecule level, making it a widely used technique in biomedical research. However, conventional approaches typically rely on fluorescence detection of single-enzyme reactions, which limits molecular selectivity and the ability to analyze multiple targets simultaneously. To address these limitations, we developed a digital bioanalysis platform based on surface-enhanced Raman scattering spectroscopy and microchamber arrays decorated with silver nanoparticles. This platform achieves a million-fold amplification of Raman signals from products generated by single-enzyme reactions, enabling precise digital counting of enzyme biomarkers with high molecular selectivity and multiplexing capability. We applied this platform to detect and distinguish two closely related enzyme biomarkers, acetylcholinesterase (AChE) and butyrylcholinesterase. By leveraging the sharp and distinct Raman spectral signatures of the reaction products, the platform achieved multiplexed biomarker quantification with femtomolar-level sensitivity. As a proof-of-concept, the platform successfully quantified AChE in human cerebrospinal fluid within 8.5 min, highlighting its potential utility in clinical diagnostics, particularly for differentiating types of dementia based on subtle differences in enzyme levels. Hence, this study presents a valuable alternative to fluorescence-based digital bioanalysis by offering enhanced molecular selectivity and multiplexing capability. Its application extends the scope of digital bioanalysis and broadens its capacity to quantify multiple biomarkers in complex biological samples with high precision and efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.